These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

206 related items for PubMed ID: 25051026

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Phenotypic and genetic characterization of varicella-zoster virus mutants resistant to acyclovir, brivudine and/or foscarnet.
    Bleymehl K, Cinatl J, Schmidt-Chanasit J.
    Med Microbiol Immunol; 2011 Aug; 200(3):193-202. PubMed ID: 21373931
    [Abstract] [Full Text] [Related]

  • 6. The development of BVDU: An odyssey.
    De Clercq E.
    Antivir Chem Chemother; 2023 Aug; 31():20402066231152971. PubMed ID: 36710501
    [Abstract] [Full Text] [Related]

  • 7. A Novel Human Skin Tissue Model To Study Varicella-Zoster Virus and Human Cytomegalovirus.
    Lloyd MG, Smith NA, Tighe M, Travis KL, Liu D, Upadhyaya PK, Kinchington PR, Chan GC, Moffat JF.
    J Virol; 2020 Oct 27; 94(22):. PubMed ID: 32878893
    [Abstract] [Full Text] [Related]

  • 8. Lack of susceptibility of bicyclic nucleoside analogs, highly potent inhibitors of varicella-zoster virus, to the catabolic action of thymidine phosphorylase and dihydropyrimidine dehydrogenase.
    Balzarini J, Sienaert R, Liekens S, Van Kuilenburg A, Carangio A, Esnouf R, De Clercq E, McGuigan C.
    Mol Pharmacol; 2002 May 27; 61(5):1140-5. PubMed ID: 11961132
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Utility of ultra-deep sequencing for detection of varicella-zoster virus antiviral resistance mutations.
    Mercier-Darty M, Boutolleau D, Lepeule R, Rodriguez C, Burrel S.
    Antiviral Res; 2018 Mar 27; 151():20-23. PubMed ID: 29337163
    [Abstract] [Full Text] [Related]

  • 14. Metabolism and mode of inhibition of varicella-zoster virus by L-beta-5-bromovinyl-(2-hydroxymethyl)-(1,3-dioxolanyl)uracil is dependent on viral thymidine kinase.
    Li L, Dutschman GE, Gullen EA, Tsujii E, Grill SP, Choi Y, Chu CK, Cheng YC.
    Mol Pharmacol; 2000 Nov 27; 58(5):1109-14. PubMed ID: 11040060
    [Abstract] [Full Text] [Related]

  • 15. In vitro susceptibility of varicella-zoster virus to E-5-(2-bromovinyl)-2'-deoxyuridine and related compounds.
    De Clercq E, Descamps J, Ogata M, Shigeta S.
    Antimicrob Agents Chemother; 1982 Jan 27; 21(1):33-8. PubMed ID: 6282207
    [Abstract] [Full Text] [Related]

  • 16. (E)-5-(2-bromovinyl)-2'-deoxyuridine (BVDU).
    De Clercq E.
    Med Res Rev; 2005 Jan 27; 25(1):1-20. PubMed ID: 15389733
    [Abstract] [Full Text] [Related]

  • 17. Bicyclic pyrimidine nucleoside analogues (BCNAs) as highly selective and potent inhibitors of varicella-zoster virus replication.
    Balzarini J, McGuigan C.
    J Antimicrob Chemother; 2002 Jul 27; 50(1):5-9. PubMed ID: 12096000
    [Abstract] [Full Text] [Related]

  • 18. Herpes zoster guideline of the German Dermatology Society (DDG).
    Gross G, Schöfer H, Wassilew S, Friese K, Timm A, Guthoff R, Pau HW, Malin JP, Wutzler P, Doerr HW.
    J Clin Virol; 2003 Apr 27; 26(3):277-89; discussion 291-3. PubMed ID: 12637076
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.